The startup plans to use the funds to scale its single-cell DNA analysis technology for blood-based cancer research and expand into CRISPR applications.
The life science research tools firm is offering 8,150,000 shares of its common stock at a price of $6.75 per share for gross proceeds of about $55 million.
The funding is being provided to a number of early-career investigators and collaborative research groups using genomics and other technologies.
In Science this week: single-cell analysis of colorectal cancers finds genome-wide demethylation patterns, and more.
The researchers reported that targeting HDAC4 in the patient-derived neurons appeared to correct the expression of genes that differed in the disease state.
Researchers identified immune activity changes in first-trimester placenta and decidua samples profiled through single-cell RNA sequencing.
Using a mouse model of immunotherapy resistant disease, the researchers found that this program could be targeted by an inhibitor to improve response.
Researchers identified 133 neuronal and non-neuronal cell types using single-cell RNA-seq data for tens of thousands of cells from the mouse neocortex.
The platform uses a gravity-based method to capture and isolate up to 100,000 individual cells per run, while maintaining viability and structural integrity.
The researchers found that genes whose transcription in response to an immune challenge diverged across species also varied between single cells.
23andMe is offering early customers re-testing on newer chips for a fee, Wired reports.
He Jiankui is no longer affiliated with Direct Genomics Biotechnology, the single molecule sequencing company he founded, Nikkei Asian Review reports.
Newsweek writes about the hopes for precision medicine in cancer, but also challenges getting it to patients.
In Genome Research this week: genomic architecture of glioblastoma, predictive computational approach to estimate SNP fitness, and more.